A randomized controlled multicenter trial of actovegin against acute oral mucositis induced by chemo-radiotherapy for nasopharyngeal carcinoma

( views:348, downloads:0 )
Author:
CUI Tian-tian(State Key Laboratory of Ontology in South China,Departmerit of Radiation Oncology , Cancer Center, Sun Yat-Sen University, Guangzhou 510060, China)
ZHAO Chong(State Key Laboratory of Ontology in South China,Departmerit of Radiation Oncology , Cancer Center, Sun Yat-Sen University, Guangzhou 510060, China)
WU Shao-xiong(State Key Laboratory of Ontology in South China,Departmerit of Radiation Oncology , Cancer Center, Sun Yat-Sen University, Guangzhou 510060, China)
PAN Jian-ji()
XU Bing-yu()
TIAN Ye()
CUI Nian-ji(State Key Laboratory of Ontology in South China,Departmerit of Radiation Oncology , Cancer Center, Sun Yat-Sen University, Guangzhou 510060, China)
Journal Title:
CHINESE JOURNAL OF RADIATION ONCOLOGY
Issue:
Volume 17, Issue 06, 2008
DOI:
Key Word:
Nasopharyngeal neoplasms/radiotherapy;Nasopharyngeal neoplasms/chemotherapy;Acute oral mucositis;Actovegin

Abstract: Objective To evaluate the efficacy and safety of actovegin against acute oral mucositis through a randomized controlled multicenter trial for nasopharyngeal carcinoma(NPC) patients treated by chemo-radiotherapy. Methods From February 2006 to May 2007,a total of 161 patients with newly diagnosed stage Ⅱ-ⅣA(1992 Fuzhou Stage) NPC were randomly assigned to the prevention group,the treatment group and the control group. All patients received current chemo-radiotherapy ± neoadjuvant chemotherapy. Radiation technique and dose were similar among the three groups. Intravenous infusion of aeovegin was started when radiation started in the prevention group and when grade 2 mueositis occurred in the treatment group,which was given 30 ml daily ,5 times per week until the end of radiotherapy. Criteria of NCI CTC 2.0 and VRS were used to evaluate acute oral mueositis and pain degree,respectively. Results 154 patients were eligible for the efficacy analysis,including 49 in the prevention group,53 in the treatment group and 52 in the control group. In the prevention group and the control group, the incidence was 31% and 56% (P=0.011) for grade 3-4 mucositis,59% and 83% (P=0.009) for grade 2-3 pain. In the treatment group and the control group,the corresponding number was 38% and 60% (P=0.023) ,70% and 90%, (P=0.014). The prevention group had a lower incidence(P=0.021) and longer average interval(P=0.009) of grade 2 mucositis when comparing with the control group. No drug-related adverse event was observed. Conclusions Prophylactic or therapeutic use of actovegin by intravenous infusion can significantly reduce the severity of ehemo-radiotherapy induced oral mucositis and pain. The prophylactic use may also postpone and decrease the incidence of grade 2 mucositis,which deserves clinic application.

  • [1]Banjat B,Audry H,Bourhis J,et al.Chemotherapy in locally advanced nasopharyngeal carcinoma:an individual patient data metaanalysis of eight randomized trials and 1753 patients,lnt J Radiat Oneol Biol Phys,2006,64:47-56.
  • [2]孙瑞,吴少雄,赵充,等.评估诱导化疗在局部晚期鼻咽癌放射治疗中的作用.肿瘤学杂志,2007,13:372-376.
  • [3]赵允,卢泰祥,韩非,等.139例鼻咽癌凋强放疗的临床研究.中华放射肿瘤学杂志,2006,15:1-6.
  • [4]Tretti A,Bellm LA,Epstein JB,et al.Mueositis incidence,severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy:a systematic literature review.Radiother Oncol,2003,66:253-262.
  • [5]Trotti A.Toxicity in head and neck cancer:a review of trends and issues.Int J Radiat Oneol Biol Phys,2000,47:1-12.
  • [6]List MA,Siston A,Haraf D,et al.Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy:a prospective examination.J Clin Oncol,1999,17:1020-1028.
  • [7]Terrell JE,Ronis DL,Fowler KE,et al.Clinical predictors of quality of life in patients with head and neck cancer.Arch Otolaryngol Head Neck Surg,2004,130:401-408.
  • [8]Parulekar W,Mackenzie R,Bjarnason G,et al.Scoring oral mucositis.Oral Oneology,1998,34:63-71.
  • [9]Sinka L,Hlavaty P.Clinical experiences with treatment of ulens cmris.Fortsch Med,1973,91:959-961.
  • [10]王和平,孙言才,金淑文,等.爱维治的临床应用及评价.安徽预防医学杂志,2000,6:158-159.
  • [11]张学成,肖锋,魏丽春,等.爱维治防治急性放射性口咽黏膜损伤的临床研究.实用口腔医学杂志,2006,22:496-498.
  • [12]刘树铮.辐射的生物化学效应//刘树铮,主编.医学放射生物学.北京:原子能出版社,1986:68-106.
  • [13]Sonis S,Clark J.Prevention and management of oral mueositis induced by antinenplastic therapy.Ontology,1991,5:11-18.
  • [14]王学军,常宝成.爱维治、弥可保和东茛若碱治疗糖尿病周围神经病变的疗效观察.天津医科大学学报,2004,10:209-211.
  • [15]于洪儒,肖建英,刘用璋,等.小牛血去蛋白注射液对脑梗塞急性期的临床疗效.中国新药杂志,2000,9:401-402.
  • [16]Barth G,Graehner HF,Lotz H.The treatment of lethal radiation damage with Actihaemyl in animal experiments.Strahlentherapie Arch Klin Exp Radiol,1969,138:714-723.
  • [17]Hoefer-Janker H,N:heef W,Dackter J.The action of an extract of calf's blood on radiation-induced lesions of the mucuous of the laryngo-pharyngeal region.Strahlentherapie Arch Kiln Exp Radiol,1970,139:701-708.
  • [18]Bauer KM.Local treatment of the urinary bladder damaged by radiation.Med Welt,1970,21:790-792.
  • [19]Heinrich W.The treatment of exadative radiadermatitis with Aetihaemyl cream.Fortschr Med,1969,18:807.
  • [20]Gruia VD,Bayerl JR.Treatment of radiation-produced arm plexus pareses with Actovegin.Fortachritte der Medizin,1981,99:161-162.
  • [21]Fritzsche W.Promotion of tumor-ulcer healing by means of a protein-free calf bloom extract.Zeitschrift für Hautu Geschlechtskrankheiten,1961,8:235-238.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn